» Articles » PMID: 35710996

The Role of ATP-binding Cassette Transporter Genes Expression in Treatment Failure Cutaneous Leishmaniasis

Overview
Journal AMB Express
Date 2022 Jun 17
PMID 35710996
Authors
Affiliations
Soon will be listed here.
Abstract

Leishmaniasis is one of the common diseases transmitted by sand flies in tropical and subtropical regions of the world. Currently, antimonial derivatives are the first line of treatment. Some of the members of the ATP-binding cassette (ABC) family of Leishmania are shown to be associated with no response to treatment. In this study, we evaluated ABCI4, ABCG2, ABCC7, ABCB4, and ABCC3 genes expression in Leishmania isolated from patients with non-healing cutaneous leishmaniasis and treatment response isolates. We selected 17 clinical isolates including 8 treatment failure and 9 treatment response samples from September 2020 to March 2021. The isolates were obtained from patients of Health Center Laboratory of Varzaneh, Isfahan, Iran with cutaneous leishmaniasis. The diagnosis was performed using microscopic observation. The samples were directly collected from the lesions. The expression profiling of genes was assessed using SYBR Green real-time PCR that was analyzed with delta-delta Ct. All treatment failure clinical isolates were L. major. Gene expression analysis in treatment failure isolates showed that the ABC transported genes had a different pattern in each isolate. Treatment failure has been reported for cutaneous leishmaniasis worldwide. Knowledge of the molecular mechanisms of treatment failure could solve this problem. ABC transporter genes are considered controversial over the mechanisms of treatment failure outcomes. In this study, we showed that ABC transporter genes could be considered one of the important mechanisms.

Citing Articles

Possibility of re-purposing antifungal drugs posaconazole & isavuconazole against promastigote form of Leishmania major.

Bhusal C, Beniwal P, Singh S, Kaur D, Kaur U, Kaur S Indian J Med Res. 2024; 160(5):466-478.

PMID: 39737513 PMC: 11683497. DOI: 10.25259/IJMR_569_2024.


Genomic Insight of Leishmania Parasite: In-Depth Review of Drug Resistance Mechanisms and Genetic Mutations.

Bharadava K, Upadhyay T, Kaushal R, Ahmad I, Alraey Y, Siddiqui S ACS Omega. 2024; 9(11):12500-12514.

PMID: 38524425 PMC: 10955595. DOI: 10.1021/acsomega.3c09400.

References
1.
Leprohon P, Fernandez-Prada C, Gazanion E, Monte-Neto R, Ouellette M . Drug resistance analysis by next generation sequencing in Leishmania. Int J Parasitol Drugs Drug Resist. 2015; 5(1):26-35. PMC: 4412915. DOI: 10.1016/j.ijpddr.2014.09.005. View

2.
Mukherjee A, Padmanabhan P, Singh S, Roy G, Girard I, Chatterjee M . Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother. 2007; 59(2):204-11. DOI: 10.1093/jac/dkl494. View

3.
Bennis I, De Brouwere V, Belrhiti Z, Sahibi H, Boelaert M . Psychosocial burden of localised cutaneous Leishmaniasis: a scoping review. BMC Public Health. 2018; 18(1):358. PMC: 5855994. DOI: 10.1186/s12889-018-5260-9. View

4.
Callahan H, Roberts W, Rainey P, Beverley S . The PGPA gene of Leishmania major mediates antimony (SbIII) resistance by decreasing influx and not by increasing efflux. Mol Biochem Parasitol. 1994; 68(1):145-9. DOI: 10.1016/0166-6851(94)00154-5. View

5.
Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M . Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006; 3(5):e162. PMC: 1435779. DOI: 10.1371/journal.pmed.0030162. View